Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
| ▸ | KCNK3 | O14649 | 5/20 | 0.50 |
| ▸ | KCNK9 | Q9NPC2 | 5/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.45 |
| ▸ | RELA | Q04206 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16539686 | 0.91 | POLB (0.55) | KCNK3KCNK9MAPK14KMT2AMEN1 | |
| SCHEMBL16539397 | 0.90 | SMN1; SMN2 (0.53) | KCNK3KCNK9MAPK14KMT2AMEN1 | |
| SCHEMBL16539756 | 0.90 | MAPK14 (0.48) | KCNK3KCNK9MAPK14KMT2AMEN1 | |
| SCHEMBL16539566 | 0.89 | NPC1 (0.56) | KCNK3KCNK9MAPK14KMT2AMEN1 | |
| SCHEMBL16538970 | 0.86 | MEN1 (0.63) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL16539241 | 0.85 | MEN1 (0.53) | KCNK3KCNK9MAPK14KMT2AMEN1 | |
| SCHEMBL16539937 | 0.85 | BRD4 (0.55) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL16539244 | 0.84 | SMN1; SMN2 (0.61) | MAPK14KMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL16539321 | 0.83 | KMT2A (0.54) | MAPK14KMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL16539464 | 0.83 | SMN1; SMN2 (0.54) | KCNK3KCNK9MAPK14KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3038612-B1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-07-29 | — | — | EP | disclosed |
| US-10351511-B2 | Cyclic vinylogous amides as bromodomain inhibitors | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180105485-A1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-04-19 | — | — | US | disclosed |
| US-9884806-B2 | Cyclic vinylogous amides as bromodomain inhibitors | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-02-06 | — | — | US | disclosed |
| US-20160200666-A1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2016-07-14 | — | — | US | disclosed |
| EP-3038612-A1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | Icahn School of Medicine at Mount Sinai (US) | 2016-07-06 | — | — | EP | disclosed |
| WO-2015031824-A9 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2015031824-A1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2015-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200666-A1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | BRD1, BRD4, BRDT | STAT3 3900/4885KCNK3 2378/4885KCNK9 1698/4885 |
| US-10351511-B2 | Cyclic vinylogous amides as bromodomain inhibitors | BRD1, BRD4, BRDT | STAT3 3900/4885KCNK3 2378/4885KCNK9 1698/4885 |
| US-20180105485-A1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | BRD1, BRD4, BRDT | STAT3 3900/4885KCNK3 2378/4885KCNK9 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.